Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Platten

Showing results (231-240 of 318) with videos related to

Pageof 32
Sort By:
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Nature Communications|May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Oncoimmunology|June 16, 2025
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastomaAlexandros Kourtesakis, Eileen Bailey, Hiu Nam Hannah Chow, et al.
Investigative Radiology|December 7, 2024
Differentiating Glioma Recurrence and Pseudoprogression by APTw CEST MRIKianush Karimian-Jazi, Noah Enbergs, Evgeny Golubtsov, et al.
Radiology|July 29, 2020
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 TrialPhilipp Kickingereder, Gianluca Brugnara, Mikkel Bo Hansen, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Nature Cancer|February 5, 2022
The current landscape of immunotherapy for pediatric brain tumorsEugene I Hwang, Elias J Sayour, Catherine T Flores, et al.
Molecular Cancer Research : MCR|February 18, 2018
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for GlioblastomaJonas Blaes, Carina M Thomé, Philipp-Niclas Pfenning, et al.
Pageof 32

Showing results (231-240 of 318) with videos related to

Sort By:
Pageof 32
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Nature Communications|May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Oncoimmunology|June 16, 2025
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastomaAlexandros Kourtesakis, Eileen Bailey, Hiu Nam Hannah Chow, et al.
Investigative Radiology|December 7, 2024
Differentiating Glioma Recurrence and Pseudoprogression by APTw CEST MRIKianush Karimian-Jazi, Noah Enbergs, Evgeny Golubtsov, et al.
Radiology|July 29, 2020
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 TrialPhilipp Kickingereder, Gianluca Brugnara, Mikkel Bo Hansen, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Nature Cancer|February 5, 2022
The current landscape of immunotherapy for pediatric brain tumorsEugene I Hwang, Elias J Sayour, Catherine T Flores, et al.
Molecular Cancer Research : MCR|February 18, 2018
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for GlioblastomaJonas Blaes, Carina M Thomé, Philipp-Niclas Pfenning, et al.
Pageof 32